Perpetua Medical AB Class B

As of June 30, 2026, Perpetua Medical AB Class B carries a market capitalization of 30.89M, placing it among publicly traded companies globally. Its enterprise value stands at 23.63M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Perpetua Medical AB Class B has 8.56M shares outstanding.

As of June 30, 2026, Perpetua Medical AB Class B trades at a trailing price-to-earnings ratio of 70.95. The price-to-sales ratio is 1.23, and the price-to-book ratio stands at 1.92.

As of June 30, 2026, Perpetua Medical AB Class B trades at an EV/EBITDA multiple of 12.26 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.21 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 23.63M versus a market cap of 30.89M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Perpetua Medical AB Class B maintains a current ratio of 3.76, meaning it holds 3.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.70, indicating moderate leverage, while an interest coverage ratio of 2.48 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Perpetua Medical AB Class B posted a return on equity (ROE) of 3.11, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 0.91, measuring how efficiently the asset base is converted into earnings. The company generates approximately 1.96M in revenue per employee across its workforce of 10.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 9.60 indicates how many times Perpetua Medical AB Class B sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Perpetua Medical AB Class B recorded an income tax benefit of -321,000.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -3.06M and 339,000.00 in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Perpetua Medical AB Class B's stock has declined approximately 53.88% over the past 52 weeks. The 50-day moving average sits at 2.71, while the 200-day moving average is 3.52.

Over the twelve months ended June 30, 2026, Perpetua Medical AB Class B generated 19.58M in revenue and converted that into 339,000.00 in net income, yielding earnings per share of -0.41. EBITDA reached 1.93M, while operating income came in at -2.36M.

As of June 30, 2026, Perpetua Medical AB Class B holds 16.83M in cash and equivalents against 178,000.00 in total debt, resulting in a net debt position of -16.65M. Total book value stands at 16.08M, with working capital of 24.30M providing operational flexibility.

Perpetua Medical AB Class B produced -6.31M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -4.41M in capital expenditures, free cash flow totaled -10.71M - equivalent to -1.61 per share.

Over the twelve months ended June 30, 2026, Perpetua Medical AB Class B posted a gross margin of 48.69, reflecting its pricing power and cost economics. The operating margin of -12.07 and net profit margin of 1.73 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -44.55: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -89.94, meaning Perpetua Medical AB Class B raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Perpetua Medical AB Class B's most recent stock split took place on September 27, 2024 with a 24:1 split ratio.

As of June 30, 2026, Perpetua Medical AB Class B has an Altman Z-Score of 1.50, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.